Many Cancer Drugs Don’t Extend Life
Big Take17 Dec

Many Cancer Drugs Don’t Extend Life

Treating cancer is a massive business. In 2024 alone, cancer treatments generated at least $200 billion in worldwide sales for the pharmaceutical industry, more than the obesity drug rush. But a Bloomberg News analysis showed that fewer than half of treatments reviewed — some of which have painful side effects — have been shown to extend patients’ lives.

On today’s Big Take podcast, Bloomberg senior healthcare reporter Robert Langreth takes host David Gura inside what some doctors call the “cancer-industrial complex” — from the regulatory landscape that ushered in a wave of lucrative new drugs to the damaging financial and health impacts some treatments can have on patients.

Read more:

Cancer Drugs Cost More Than Ever. They Often Don’t Extend Lives.

The Implants Were Supposed to Dissolve. They Didn’t.

Pharma Is Pushing $200,000 Cancer Drugs When Cheaper Doses May Work

Cancer Doctors Are Making a Fortune Off Drug-Trial Participants

One Generic Cancer Drug Costs $35. Or $134. Or $13,000.

See omnystudio.com/listener for privacy information.

Avsnitt(780)

What Happens if the Supreme Court Kicks Affirmative Action Off Campus?

What Happens if the Supreme Court Kicks Affirmative Action Off Campus?

For decades, colleges and universities across the US have promoted the value of having a diverse student body on campus.  The Supreme Court could soon change that. On Oct. 31, the justices will consider two challenges to affirmative action in college admissions, and if they choose to strike it down, there will be enormous repercussions for who gets into the nation’s top schools — and who doesn’t. So what will college campuses look like in an America without affirmative action? And are there other ways for admissions officers to work around a potential ban on the practice?  Bloomberg Senior Reporter Greg Stohr joins with insights on what we can expect from the Supreme Court, and Equality Reporter Kelsey Butler explains how colleges around the country are bracing for massive disruption.  Learn more about this story here: https://bloom.bg/3SO4b0m Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK  Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.See omnystudio.com/listener for privacy information.

31 Okt 202228min

Clash of the Streaming Titans

Clash of the Streaming Titans

Remember when everyone loved to complain how there were 150 channels on TV and nothing good to watch? It’s pretty hard to say that now. There are so many good shows being made. Our new complaint: how hard it is to watch all those great shows, especially when they’re spread across so many streaming services—and most of them you have to pay for. How did we get here?  Bloomberg media reporter Felix Gillette has answers.  He’s the co-author of the upcoming book It's Not TV: The Spectacular Rise, Revolution, and Future of HBO.Felix joins this episode to break down why TV has never been better–and yet has never been more frustrating to watch.  Bloomberg’s entertainment reporter Lucas Shaw also stops in to explain how this shift has changed the way Hollywood decides which shows get made--and which ones don't.Read the Book excerpt here: https://bloom.bg/3SI08CA Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK  Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.See omnystudio.com/listener for privacy information.

28 Okt 202229min

The US Middle Class Is Doing Fine. Why Are They So Worried?

The US Middle Class Is Doing Fine. Why Are They So Worried?

Hello and welcome to The Big Take Podcast! Today: The good news, and not so good news, about the US middle class. With inflation rising, the stock market ping-ponging and housing prices softening, that broad swath of Americans who form the backbone of the US economy are getting hit on all sides. Bloomberg reporters Shawn Donnan, Alex Tanzi, Claire Ballentine and Airielle Lowe teamed up to take a look at how middle-income Americans are doing. The answer: Not so badly, actually–at least on paper. Even so, they’re worried about what’s next for them. And they have good reason to be. Shawn sits down with Wes to share the results from their exclusive polling and what these precarious economic times mean for the fortunes of working Americans. Learn more about this story here: https://bloom.bg/3faCxwM Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK  Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.See omnystudio.com/listener for privacy information.

27 Okt 202229min

Introducing: The Big Take

Introducing: The Big Take

Each weekday, The Big Take brings you one story—one big, important story that impacts your life. Host Wes Kosova talks to Bloomberg journalists around the world, experts in their fields and the people at the center of the news to help you understand what’s happening, what it means and why it matters. Money, politics, the economy and business, energy, the environment, technology—we cover it all on The Big Take. And we do it in plain English. The Big Take features the best of Bloomberg's in-depth, original reporting from around the globe. Listen each weekday starting on Oct. 27. Learn more about The Big Take www.bloomberg.com/bigtake and subscribe to our daily newsletter https://bloom.bg/3rBmR9g.See omnystudio.com/listener for privacy information.

19 Okt 20222min

Populärt inom Politik & nyheter

aftonbladet-krim
svenska-fall
motiv
p3-krim
flashback-forever
fordomspodden
rss-viva-fotboll
rss-krimstad
aftonbladet-daily
rss-sanning-konsekvens
rss-vad-fan-hande
spar
rss-krimreportrarna
rss-frandfors-horna
blenda-2
olyckan-inifran
dagens-eko
krimmagasinet
rss-flodet
rss-expressen-dok